For the last 60 years, hormonal therapy has been the cornerstone of treatment of metastatic
prostate cancer. Unfortunately, hormonal therapy is purely palliative and improved systemic …

Prostate-specific membrane antigen (PSMA) is a type 2 integral membrane glycoprotein that
serves as an attractive target for cancer immunotherapy by virtue of its abundant and …

Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed at high
levels in prostate cancer and in tumor-associated neovasculature. In this study, we report …

Hepatocellular carcinoma (HCC) is a common primary cancer associated frequently with
hepatitis C virus (HCV). To gain insight into the molecular mechanisms of …

Background A detailed understanding is evolving as to how androgen receptor (AR)
functions as a transcriptional regulator via its binding to androgen response elements (ARE) …

Prostate specific membrane antigen (PSMA) is a folate glutamyl carboxypeptidase that is
oriented on the plasma membrane of normal and prostate cancer cells. A cytosolic version of …

Immunotherapy is currently being investigated as a treatment for patients with asymptomatic,
recurrent prostate cancer manifested only by a rising prostate-specific antigen (PSA) level …

Prostate-specific membrane antigen (PMSA) is an integral membrane protein highly
expressed by prostate cancer cells. We reported previously that PSMA undergoes …

A series of hydroxamic acids has been prepared as potential inhibitors of glutamate
carboxypeptidase II (GCP II). Compounds based on a P1′ residue (primed-side inhibitors) …

Prostate-specific-membrane-antigen (PSMA) is a marker protein expressed primarily in
prostate epithelium. Its prostate-specific expression is conferred by PSMA enhancer (PSME) …